Bezlotoxumab,
does it really help with Prevention of recurrent C. difficile infection after standard antibiotic treatment?
research showsBezlotoxumab is rated B because adding it to standard antibiotics reduces recurrent C. difficile infection. In the independently powered MODIFY I and II trials involving 2,655 adults, 12-week recurrence fell from 28% and 26% with placebo to 17% and 16% with bezlotoxumab. Recurrence is a direct clinical endpoint, but the drug does not treat acute infection, benefit is targeted to patients at recurrence risk, and heart-failure safety limits selection, giving 75 points.
ads claimCalling it a C. difficile treatment or complete recurrence prevention is inaccurate. Unlike the antibiotic fidaxomicin, this is a one-time toxin B-neutralizing adjunct used with standard antibiotic treatment to reduce recurrence.
Useful facts when choosing a product
- Zinplava is a prescription monoclonal antibody administered once at 10 mg/kg over 60 minutes during antibiotic treatment for CDI.
- It does not directly treat active C. difficile infection and must be used with appropriate antibacterial therapy.
- Nausea, fever, headache, and infusion-related reactions can occur.
- Heart failure and death were more frequent among trial participants with pre-existing congestive heart failure, so use in that population is reserved for cases in which benefit outweighs risk.
What the research actually shows
Wilcox and the MODIFY I and II Investigators randomized 2,655 adults receiving standard oral antibiotics for primary or recurrent CDI to bezlotoxumab, antibody combinations, or placebo. Twelve-week recurrence with one 10-mg/kg infusion was 17% versus 28% in MODIFY I and 16% versus 26% in MODIFY II. Initial clinical cure was 80% in both bezlotoxumab and placebo groups, while sustained cure was 64% versus 54%. Prespecified and post hoc risk analyses support larger absolute benefit among patients with older age, previous recurrence, immunocompromise, or other recurrence risks.
Why this is classified as B (75)
Two large phase 3 randomized trials consistently reduced 12-week clinical recurrence by approximately 10 percentage points when bezlotoxumab was added to standard antibiotics. Lack of superior initial cure, adjunctive use, manufacturer funding, and the heart-failure precaution give B with 75 points.
Counterpoint. Patients with previous recurrence, older age, immunocompromise, or severe CDI are most likely to obtain a large absolute benefit.
Rejudgment record. New verdict — Applied B because the ingredient-specific toxin B antibody consistently reduced 12-week clinical recurrence by about 10 percentage points when added to standard antibiotics in the large MODIFY I and II randomized trials
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of CDI recurrence within 12 weeks after standard antibiotics | B | Two large randomized trials consistently reduced recurrence by about 10 percentage points. |
| Increased sustained clinical cure without recurrence | B | Initial cure was unchanged, but fewer recurrences increased sustained cure from 54% to 64%. |
| Reduced recurrence in patients at high risk of recurrence | B | Absolute benefit was larger in patients with older age, previous CDI, immunocompromise, or other risk factors. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| MODIFY I and MODIFY II (Wilcox MH et al.). 2017 | Two phase 3 multicenter randomized double-blind placebo-controlled trials | 2,655 | Merck | CDI recurrence within 12 weeks after initial clinical cure | Recurrence fell to 17% versus 28% in MODIFY I and 16% versus 26% in MODIFY II. | Pivotal large randomized evidence for direct recurrence prevention |
| Gerding DN et al. pooled MODIFY risk analysis. 2018 | Pooled analysis of prespecified risk factors from two randomized trials | 1,554 | Merck | Twelve-week recurrence and readmission by risk factor | Reduced recurrence and greater absolute benefit were observed in participants with recurrence risk factors. | Supportive patient-selection analysis |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Bezlotoxumab x prevention of C. difficile recurrence after standard antibiotics — Evidence Grade B·75. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/bezlotoxumab-clostridioides-difficile-recurrence-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.